Q3 saw 5% sales growth and a 22% EBITDA increase, with strong performance in materials and IVD, but continued weakness in automotive. CapEx is ramping up for a major project, and medical supply chain adjustments may persist into Q4.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.